Differential Pattern of Soluble Immune Markers in Asymptomatic Dengue, West Nile and Zika Virus Infections.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 11 2019
Historique:
received: 19 08 2019
accepted: 04 11 2019
entrez: 22 11 2019
pubmed: 22 11 2019
medline: 5 11 2020
Statut: epublish

Résumé

Infections with dengue virus (DENV), West Nile virus (WNV) and Zika virus (ZIKV) usually present similar mild symptoms at early stages, and most infections (~80%) are asymptomatic. However, these infections may progress to severe disease with different clinical manifestations. In this study we attempted to identify unique characteristics for each infection at the presymptomatic/asymptomatic stage of infection and compared levels of soluble immune markers that have been shown to be altered during clinical course of these viral infections. Levels of soluble markers were determined by Luminex-based assays or by ELISA in plasma samples from asymptomatic blood donors who were reactive for RNA from DENV (n = 71), WNV (n = 52) or ZIKV (n = 44), and a control or non-infected (NI) group (n = 22). Results showed that even in the absence of symptoms, increased interleukin (IL) levels of IL-12, IL-17, IL-10, IL-5, CXCL9, E-Selectin and ST2/IL-1R4; and decreased levels of IL-13 and CD40 were found in all flavivirus group samples, compared to those from NI donors. DENV-infected donors demonstrated variation in expression of IL-1ra and IL-2; WNV-infected donors demonstrated variation in expression of IL-1ra, P-Selectin, IL-4 and IL-5; ZIKV-infected donors demonstrated variation in expression of IL-1ra, P-Selectin, IL-4, RANK-L, CD40L and C3a. The findings suggest that, even in the presymptomatic/asymptomatic phase of the infection, different immunomodulation profiles were associated with DENV, WNV and ZIKV infections.

Identifiants

pubmed: 31748599
doi: 10.1038/s41598-019-53645-w
pii: 10.1038/s41598-019-53645-w
pmc: PMC6868147
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Biomarkers 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

17172

Références

Mol Med. 2008 Jul-Aug;14(7-8):476-84
pubmed: 18431461
J Biomed Sci. 2015 Oct 14;22:83
pubmed: 26462910
J Immunol. 2004 Jul 1;173(1):307-13
pubmed: 15210788
J Immunol. 2006 Sep 1;177(5):3185-92
pubmed: 16920957
J Infect Dis. 2017 Jul 15;216(2):172-181
pubmed: 28838147
Front Microbiol. 2014 Nov 26;5:627
pubmed: 25505454
J Infect Dis. 2018 Jul 24;218(5):814-824
pubmed: 29672707
J Immunol. 2006 Nov 1;177(9):6497-503
pubmed: 17056582
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Am J Pathol. 2013 Jun;182(6):1950-61
pubmed: 23567637
Lancet. 2017 Aug 26;390(10097):861-870
pubmed: 28647172
Curr Top Microbiol Immunol. 2010;338:67-82
pubmed: 19802579
BMC Infect Dis. 2008 Jun 25;8:86
pubmed: 18578883
Science. 1997 Aug 8;277(5327):815-8
pubmed: 9242610
J Infect Dis. 2011 Sep 15;204(6):873-83
pubmed: 21849284
J Exp Med. 2000 Aug 21;192(4):565-70
pubmed: 10952726
N Engl J Med. 2009 Jun 11;360(24):2536-43
pubmed: 19516034
OMICS. 2017 Nov;21(11):665-677
pubmed: 29091011
Med Microbiol Immunol. 2016 Jun;205(3):269-73
pubmed: 26702627
Nature. 2013 Apr 25;496(7446):504-7
pubmed: 23563266
Emerg Infect Dis. 2014 Jun;20(6):1085-6
pubmed: 24856001
Viruses. 2017 Apr 30;9(5):
pubmed: 28468299
PLoS One. 2012;7(7):e38527
pubmed: 22815692
Nat Immunol. 2017 May 18;18(6):612-621
pubmed: 28518156
Immunol Cell Biol. 2007 Jan;85(1):43-5
pubmed: 17130899
Nature. 2017 Jun 15;546(7658):406-410
pubmed: 28538727
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
Biomed Res Int. 2015;2015:376230
pubmed: 25866777
J Infect Dis. 2008 Oct 1;198(7):979-83
pubmed: 18729779
Blood. 2003 Apr 1;101(7):2652-60
pubmed: 12456506
Viral Immunol. 2014 Mar;27(2):39-47
pubmed: 24605787
Nat Rev Immunol. 2005 Apr;5(4):331-42
pubmed: 15803152
Emerg Infect Dis. 2009 Sep;15(9):1347-50
pubmed: 19788800
PLoS Pathog. 2012;8(11):e1003039
pubmed: 23209411
Viral Immunol. 2006 Spring;19(1):3-9
pubmed: 16553546
Mem Inst Oswaldo Cruz. 2018 May 14;113(6):e170542
pubmed: 29768624
J Virol. 2016 Dec 16;91(1):
pubmed: 27795421
Virology. 2014 Mar;452-453:42-51
pubmed: 24606681
Annu Rev Immunol. 2018 Apr 26;36:489-517
pubmed: 29400998
Immunity. 2012 May 25;36(5):705-16
pubmed: 22633458
Nat Rev Immunol. 2011 Jul 15;11(8):532-43
pubmed: 21760609
Transfusion. 2016 Jan;56(1):215-22
pubmed: 26469514
Open Forum Infect Dis. 2018 Apr 07;5(4):ofy073
pubmed: 29732381
Emerg Infect Dis. 2015 Oct;21(10):1885-6
pubmed: 26401719
PLoS One. 2012;7(12):e52215
pubmed: 23284941
J Immunol. 2005 Jan 1;174(1):395-403
pubmed: 15611263
Front Immunol. 2014 Jun 11;5:280
pubmed: 24966859
Viruses. 2014 Feb 06;6(2):606-23
pubmed: 24509812
Emerg Infect Dis. 1995 Apr-Jun;1(2):55-7
pubmed: 8903160
FEMS Immunol Med Microbiol. 2000 Jun;28(2):151-5
pubmed: 10799806
Ann Trop Paediatr. 2007 Sep;27(3):179-84
pubmed: 17716445
J Gen Virol. 2009 Aug;90(Pt 8):1827-1835
pubmed: 19369409

Auteurs

Rafaelle Fares-Gusmao (R)

Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.

Bruno Coelho Rocha (BC)

Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.

Emilia Sippert (E)

Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.

Marion C Lanteri (MC)

Blood Systems Research Institute, San Francisco, CA, USA.
Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.

Germán Áñez (G)

Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
Sanofi Pasteur, Swiftwater, PA, USA.

Maria Rios (M)

Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA. maria.rios@fda.hhs.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH